Acumen and deCODE Chemistry Initiate Drug Discovery Research
Complete the form below to unlock access to ALL audio articles.
Acumen Pharmaceuticals and deCODE chemistry have initiated a drug discovery program to identify potential therapeutic treatments for Alzheimer’s Disease.
The program will initially involve a hit-to-lead campaign focused on exploring the high-quality screening hits that Acumen identified in its small molecule anti-ADDLplatform.
As validated lead series develop, deCODE chemistry will conduct lead optimization focused on potency in Acumen’s assay and optimization of pharmaceutical properties.
Under the terms of the agreement, deCODE chemistry will provide medicinal chemistry services to Acumen on a fee- for-service basis, to include services from the Medicinal Chemistry and Drug Safety and Metabolism groups of deCODE chemistry.
"We are delighted to have the opportunity to work with Acumen Pharmaceuticals on this exciting research program," said Dr. David Zembower, Vice President of Chemistry at deCODE chemistry.
"Our service platform is ideally suited to help advance Acumen’s research program and allow them to achieve their corporate goals."
"After an in-depth evaluation of many service providers, we were very pleased to select deCODE chemistry as Acumen’s medicinal chemistry services provider," said Dr. William Goure, Vice President of Business Development and Director of Chemistry at Acumen.
"We have been working with deCODE chemistry for several months, and they have met all our expectations of providing high quality medicinal chemistry to advance Acumen’s drug discovery and development program."
